keyword
MENU ▼
Read by QxMD icon Read
search

chemotherapy metastatic breast cancer

keyword
https://www.readbyqxmd.com/read/29910660/the-evolution-of-biosimilars-in-oncology-with-a-focus-on-trastuzumab
#1
N A Nixon, M B Hannouf, S Verma
Cancer therapy has evolved significantly with increased adoption of biologic agents ("biologics"). That evolution is especially true for her2 (human epidermal growth factor receptor-2)-positive breast cancer with the introduction of trastuzumab, a monoclonal antibody against the her2 receptor, which, in combination with chemotherapy, significantly improves survival in both metastatic and early disease. Although the efficacy of biologics is undeniable, their expense is a significant contributor to the increasing cost of cancer care...
June 2018: Current Oncology
https://www.readbyqxmd.com/read/29910659/value-assessment-in-oncology-drugs-funding-of-drugs-for-metastatic-breast-cancer-in-canada
#2
J Lemieux, S Audet
Background: Life expectancy for women with metastatic breast cancer has improved since the early 2000s, in part because of the introduction of novel therapies, including chemotherapy, hormonal therapy, and targeted agents. However, those treatments can come at a cost for the patient (short- and long-term toxicities from treatment) and at a financial cost for the health care system. Given the increase in the number of costly anticancer agents being introduced into the clinical setting, the American Society of Clinical Oncology (asco) and the European Society for Medical Oncology (esmo) have developed a system to quantify the value of new cancer treatments in terms of benefit, toxicities, and costs...
June 2018: Current Oncology
https://www.readbyqxmd.com/read/29910657/advances-in-the-systemic-treatment-of-triple-negative-breast-cancer
#3
REVIEW
J M Lebert, R Lester, E Powell, M Seal, J McCarthy
Triple-negative breast cancer constitutes a heterogeneous group of malignancies that are often aggressive and associated with a poor prognosis. Molecular characterization, while not a standard of care, can further subtype triple-negative breast cancer and provide insight into prognostication and behaviour. Optimal chemotherapy regimens have yet to be established; however, there have been advances in the systemic treatment of triple-negative breast cancer in the neoadjuvant, adjuvant, and metastatic settings...
June 2018: Current Oncology
https://www.readbyqxmd.com/read/29909259/survival-benefit-of-surgical-removal-of-primary-tumor-in-patients-with-stage-iv-breast-cancer
#4
Hye Jin Kim, Eunyoung Kang, Jee Hyun Kim, Se Hyun Kim, Yu Jung Kim, In Ah Kim, Keun-Yong Eom, Su Min Chae, Kyu Min Kang, Eun Kyu Kim, Sung-Won Kim
BACKGROUND: Several studies have suggested that primary tumor removal improved overall survival for patients with stage IV breast cancer. However, the survival benefit of local treatment remains controversial. The purpose of the present study was to determine whether surgical removal of the primary tumor provides survival benefits to patients with stage IV breast cancer. PATIENTS AND METHODS: We retrospectively reviewed the medical records of 155 patients with an initial diagnosis of stage IV breast cancer at Seoul National University Bundang Hospital from 2003 to 2014...
May 28, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29905759/biomarker-assessment-of-the-cbcsg006-trial-a-randomized-phase-iii-trial-of-cisplatin-plus-gemcitabine-compared-with-paclitaxel-plus-gemcitabine-as-first-line-therapy-for-patients-with-metastatic-triple-negative-breast-cancer
#5
J Zhang, Y Lin, X J Sun, B Y Wang, Z H Wang, J F Luo, L P Wang, S Zhang, J Cao, Z H Tao, J Wu, Z M Shao, W T Yang, X C Hu
Background: CBCSG006 trial reported the superior efficacy of cisplatin plus gemcitabine (GP) regimen than paclitaxel plus gemcitabine (GT) regimen as first-line treatment of metastatic triple-negative breast cancer (mTNBC). This study focused on the updated survival data and the explorations of potential biomarkers for efficacy. Patients and methods: Germ-line mutations of homologous recombination (HR) panel, BRCA1/2 included, were evaluated in 55.9% (132/236) patients...
June 14, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29902087/treatment-of-advanced-breast-cancer-with-a-metronomic-schedule-of-oral-vinorelbine-what-is-the-opinion-of-italian-oncologists
#6
Marina E Cazzaniga, Elisabetta Munzone, Emilia Montagna, Giovanni Pappagallo
BACKGROUND: The aim of this study was to record the opinions of Italian oncologists about the use of oral vinorelbine administered metronomically in patients with advanced breast cancer. METHODS: A series of meetings were held throughout Italy and participants were asked how much they agreed with each of several statements. RESULTS: The majority of oncologists agreed that the concept of the minimum biologically effective dose should be used for drugs administered metronomically...
June 14, 2018: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/29898755/simultaneous-blockade-of-il-6-and-ccl5-signaling-for-synergistic-inhibition-of-triple-negative-breast-cancer-growth-and-metastasis
#7
Kideok Jin, Niranjan B Pandey, Aleksander S Popel
BACKGROUND: Metastatic triple-negative breast cancer (TNBC) is a heterogeneous and incurable disease. Numerous studies have been conducted to seek molecular targets to treat TNBC effectively, but chemotherapy is still the main choice for patients with TNBC. We have previously presented evidence of the important roles of interleukin-6 (IL-6) and chemokine (C-C motif) ligand 5 (CCL5) in TNBC tumor growth and metastasis. These experiments highlighted the importance of the crosstalk between cancer cells and stromal lymphatic endothelial cells (LECs) in tumor growth and metastasis...
June 14, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29898752/generation-of-her2-specific-antibody-immunity-during-trastuzumab-adjuvant-therapy-associates-with-reduced-relapse-in-resected-her2-breast-cancer
#8
Nadine Norton, Nicholas Fox, Christie-Ann McCarl, Kathleen S Tenner, Karla Ballman, Courtney L Erskine, Brian M Necela, Donald Northfelt, Winston W Tan, Carmen Calfa, Mark Pegram, Gerardo Colon-Otero, Edith A Perez, Raphael Clynes, Keith L Knutson
BACKGROUND: Resected HER2 breast cancer patients treated with adjuvant trastuzumab and chemotherapy have superior survival compared to patients treated with chemotherapy alone. We previously showed that trastuzumab and chemotherapy induce HER2-specific antibodies which correlate with improved survival in HER2 metastatic breast cancer patients. It remains unclear whether the generation of immunity required trastuzumab and whether endogenous antibody immunity is associated with improved disease-free survival in the adjuvant setting...
June 14, 2018: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29895438/phase-2-study-of-dose-dense-doxorubicin-and-cyclophosphamide-followed-by-eribulin-mesylate-with-or-without-prophylactic-growth-factor-for-adjuvant-treatment-of-early-stage-human-epidermal-growth-factor-receptor-2-negative-breast-cancer
#9
Karen A Cadoo, Peter A Kaufman, Andrew D Seidman, Cassandra Chang, Dongyuan Xing, Tiffany A Traina
BACKGROUND: Eribulin has significantly improved overall survival for patients with metastatic breast cancer who received ≥ 2 prior chemotherapy regimens for advanced disease. This trial assessed eribulin as adjuvant therapy for patients with early-stage breast cancer. PATIENTS AND METHODS: Patients with human epidermal growth factor receptor 2-negative, stage I to III breast cancer received doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 provided intravenously on day 1 of each 14-day cycle for 4 cycles, with pegfilgrastim on day 2, followed by 4 cycles of eribulin mesylate 1...
April 7, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29895124/smac-protein-expression-as-a-potent-favorable-prognostic-factor-in-locally-advanced-breast-cancer
#10
Piotr Pluta, Dorota Jesionek-Kupnicka, Joanna Kubicka-Wołkowska, Agnieszka Pluta, Kamil Brzozowski, Piotr Potemski, Janusz Piekarski, Radzisław Kordek, Arkadiusz Jeziorski
Preoperative systemic therapy including neoadjuvant chemotherapy (NCT) is standard treatment in locally advanced breast cancer (LABC), the aim of which is to enable a radical surgery and to reduce the risk of local and distant recurrence. It has been established that NCT in LABC may effectively induce apoptosis. The study objective was to assess the role of a proapoptotic second mitochondria-derived activator of apoptosis (SMAC) in LABC. The study group comprised 56 patients with advanced non-metastatic breast cancer (stage IIB -node positive and III), who received NCT followed by surgery and adjuvant treatment...
2018: Polish Journal of Pathology: Official Journal of the Polish Society of Pathologists
https://www.readbyqxmd.com/read/29893791/trastuzumab-versus-observation-for-her2-non-amplified-early-breast-cancer-with-circulating-tumor-cells-eortc-90091-10093-big-1-12-treat-ctc-a-randomized-phase-2-trial
#11
M Ignatiadis, S Litière, F Rothe, S Riethdorf, C Proudhon, T Fehm, K Aalders, H Forstbauer, P Fasching, E Brain, P Vuylsteke, E Guardiola, R Lorenz, K Pantel, K Tryfonidis, W Janni, M Piccart, C Sotiriou, B Rack, J-Y Pierga
Background: Trastuzumab improves the outcome of women with HER2 positive breast cancer. We aimed to assess whether trastuzumab decreases the detection rate of Circulating Tumor Cells (CTCs) in women with high risk, HER2 non-amplified, early breast cancer. Patients and Methods: The EORTC 90091-10093 BIG 1-12 Treat CTC is a phase 2 trial, conducted in 70 hospitals and 6 CTC laboratories across 5 European countries. Patients with centrally confirmed HER2 non-amplified breast cancer and ≥1 centrally confirmed CTC per 15mL of blood by CellSearch® following surgery and (neo)adjuvant chemotherapy were randomized (1:1) to 6 cycles of trastuzumab intravenously versus 18 weeks of observation...
June 11, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29890364/oxygen-boosted-immunogenic-photodynamic-therapy-with-gold-nanocages-manganese-dioxide-to-inhibit-tumor-growth-and-metastases
#12
Ruijing Liang, Lanlan Liu, Huamei He, Zhikuan Chen, Zhiqun Han, Zhenyu Luo, Zhihao Wu, Mingbing Zheng, Yifan Ma, Lintao Cai
Metastatic triple-negative breast cancer (mTNBC) is an aggressive disease among women worldwide, characterized by high mortality and poor prognosis despite systemic therapy with radiation and chemotherapies. Photodynamic therapy (PDT) is an important strategy to eliminate the primary tumor, however its therapeutic efficacy against metastases and recurrence is still limited. Here, we employed a template method to develop the core-shell gold nanocage@manganese dioxide (AuNC@MnO2 , AM) nanoparticles as tumor microenvironment responsive oxygen producers and near-infrared (NIR)-triggered reactive oxygen species (ROS) generators for oxygen-boosted immunogenic PDT against mTNBC...
May 31, 2018: Biomaterials
https://www.readbyqxmd.com/read/29880896/the-neutrophil-to-lymphocyte-and-platelet-to-lymphocyte-ratios-predict-efficacy-of-platinum-based-chemotherapy-in-patients-with-metastatic-triple-negative-breast-cancer
#13
Claudio Vernieri, Alessia Mennitto, Michele Prisciandaro, Veronica Huber, Monica Milano, Lucia Rinaldi, Maria Silvia Cona, Claudia Maggi, Benvenuto Ferrari, Siranoush Manoukian, Gabriella Mariani, Giulia Bianchi, Giuseppe Capri, Licia Rivoltini, Filippo de Braud
Platinum salts are active against metastatic triple negative breast cancer (mTNBC), and biomarkers to predict their effectiveness are urgently needed. In recent years, the neutrophil-to-lymphocyte ratio (NLR) and the platelet-to-lymphocyte ratio (PLR) have emerged as prognostic biomarkers in many malignancies, but their predictive role in platinum-treated mTNBC patients remains unexplored. We performed a retrospective, single centre study to evaluate the association between baseline NLR or PLR and progression free survival (PFS) of mTNBC patients treated with platinum-based chemotherapy...
June 7, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29878901/dz-2384-has-a-superior-preclinical-profile-to-taxanes-for-the-treatment-of-triple-negative-breast-cancer-and-is-synergistic-with-anti-ctla-4-immunotherapy
#14
Cynthia Bernier, Ahmed Soliman, Michel Gravel, Matthew Dankner, Paul Savage, Kevin Petrecca, Morag Park, Peter M Siegel, Gordon C Shore, Anne Roulston
Triple-negative breast cancer (TNBC) is typically aggressive, difficult to treat, and commonly metastasizes to the visceral organs and soft tissues, including the lungs and the brain. Taxanes represent the most effective and widely used therapeutic class in metastatic TNBC but possess limiting adverse effects that often result in a delay, reduction, or cessation of their use. DZ-2384 is a candidate microtubule-targeting agent with a distinct mechanism of action and strong activity in several preclinical cancer models, with reduced toxicities...
June 6, 2018: Anti-cancer Drugs
https://www.readbyqxmd.com/read/29878040/nab-paclitaxel-plus-carboplatin-or-gemcitabine-vs-gemcitabine-plus-carboplatin-as-first-line-treatment-for-patients-with-triple-negative-metastatic-breast-cancer-results-from-the-tnacity-trial
#15
D A Yardley, R Coleman, P Conte, J Cortes, A Brufsky, M Shtivelband, R Young, C Bengala, H Ali, J Eakel, A Schneeweiss, L de la Cruz-Merino, S Wilks, J O'Shaughnessy, S Glück, H Li, J Miller, D Barton, N Harbeck
Background: Metastatic triple-negative breast cancer (mTNBC) has a poor prognosis and aggressive clinical course. tnAcity evaluated the efficacy and/safety of first-line nab-paclitaxel plus carboplatin (nab-P/C), nab-paclitaxel plus gemcitabine (nab-P/G), and gemcitabine plus carboplatin (G/C) in patients with mTNBC. Patients and methods: Patients with pathologically confirmed mTNBC and no prior chemotherapy for metastatic BC received (1:1:1) nab-P 125 mg/m2 plus C AUC 2, nab-P 125 mg/m2 plus G 1000 mg/m2, or G 1000 mg/m2 plus C AUC 2, all on days 1, 8 q3w...
June 6, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29875947/-toxidermy-mimicking-acute-chemotherapy-induced-lupus-erythematosus
#16
Saoussane Kharmoum, Meryem Soughi
Acute chemotherapy-induced lupus erythematosus (ALE) is rare. A few cases have been reported in the literature criminalizing capecitabine, paclitaxel and docetaxel. We report the case of a 64-year old female patient without a history of autoimmune diseases or of drug allergy followed up for invasive ductal carcinoma in the right breast immediately metastatized to the liver and to the lymph nodes. After AC60 first line chemotherapy regimen (a total of 6 cycles), she was treated with docetaxel at a dose of 100 mg/m2 ...
2018: Pan African Medical Journal
https://www.readbyqxmd.com/read/29875927/descriptive-study-of-triple-negative-breast-cancer-in-eastern-algeria
#17
Haddad Souad, Frimeche Zahia, Lakehal Abdelhak, Sifi Karima, Satta Dalila, Abadi Noureddine
Introduction: Triple-negative breast cancer (TNBC) is characterized by the lack of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 (HER-2) expression. It is aggressive and most common in African women. In this study we identified the frequency, clinical an pathological characteristics of this type in a cohort of women in Eastern Algeria. Methods: We conducted a retrospective study between January 2010 and December 2015 at the regional hospital of Constantine in eastern Algeria...
2018: Pan African Medical Journal
https://www.readbyqxmd.com/read/29874851/ripk2-new-elements-in-modulating-inflammatory-breast-cancer-pathogenesis
#18
Alaa Zare, Alexandra Petrova, Mehdi Agoumi, Heather Amstrong, Gilbert Bigras, Katia Tonkin, Eytan Wine, Shairaz Baksh
Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer that is associated with significantly high mortality. In spite of advances in IBC diagnoses, the prognosis is still poor compared to non-IBC. Due to the aggressive nature of the disease, we hypothesize that elevated levels of inflammatory mediators may drive tumorigenesis and metastasis in IBC patients. Utilizing IBC cell models and patient tumor samples, we can detect elevated NF-κB activity and hyperactivation of non-canonical drivers of NF-κB (nuclear factor kappaB)-directed inflammation such as tyrosine phosphorylated receptor-interacting protein kinase 2 (pY RIPK2), when compared to non-IBC cells or patients...
June 5, 2018: Cancers
https://www.readbyqxmd.com/read/29874597/a-targeted-nanoplatform-co-delivering-chemotherapeutic-and-antiangiogenic-drugs-as-a-tool-to-reverse-multidrug-resistance-in-breast-cancer
#19
Fengchun Tian, Fatima Zohra Dahmani, Jianan Qiao, Jiang Ni, Hui Xiong, Tengfei Liu, Jianping Zhou, Jing Yao
Several obstacles are currently impeding the successful treatment of breast cancer, namely impaired drug accumulation into the tumor site, toxicity to normal cells and narrow therapeutic index of chemotherapy, multidrug resistance (MDR) and the metastatic spread of cancer cells through the blood and lymphatic vessels. In this regard, we designed a novel multifunctional nano-sized drug delivery system based on LyP-1 peptide-modified low-molecular-weight heparin-quercetin conjugate (PLQ). This nanosystem was developed for targeted co-delivery of multiple anticancer drugs to p32-overexpressing tumor cells and peritumoral lymphatic vessels, using LyP-1 peptide as active targeting ligand, with the aim to achieve a targeted combinatorial chemo/angiostatic therapy and MDR reversal...
June 3, 2018: Acta Biomaterialia
https://www.readbyqxmd.com/read/29866240/primary-mammary-small-cell-carcinoma
#20
Saima Madiha Shabbir, Syed Mohsin Raza, Sohail Murad Bhatti
Neuroendocrine breast cancer was defined in 2003 by WHO as a separate and unique breast cancer subtype. Primary small cell carcinoma of the breast, an exceptionally uncommon and aggressive tumor, is frequently characterised by early progression and worse outcome. Moreover, it is essential to distinguish between small cell carcinoma arising primarily in the breast and the metastatic disease to the breast. We had a patient of primary small cell carcinoma of breast. As her initial metastatic workup was negative for disease elsewhere, so she was started on neoadjuvant chemotherapy to which she responded well...
June 2018: Journal of the College of Physicians and Surgeons—Pakistan: JCPSP
keyword
keyword
117545
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"